Scisparc Invest Information

Companies
SciSparc Ltd. Signs Exclusive License Agreement with Polyrizon for Cannabinoid-Based Pain Therapy Aug 20, 2024
Pharmaceuticals
SciSparc Advances Autism Spectrum Disorder Treatment with SCI-210 Clinical Trial Progression Mar 1, 2024
Pharmaceuticals
SciSparc Ltd. (NASDAQ:SPRC) Soars on Positive Clinical Trial Launch Nov 25, 2023
Investment
SciSparc Ltd. Embarks on Transformative Phase IIb Trial for Tourette Syndrome Using THC-Based Medication Nov 11, 2023